Literature DB >> 15276691

Effect of switching to atypical antipsychotics on memory in patients with chronic schizophrenia.

Kazuhiko Mori1, Masatsugu Nagao, Hidehisa Yamashita, Shigeru Morinobu, Shigeto Yamawaki.   

Abstract

While the usefulness of atypical antipsychotics for improving cognitive function has been proven, the specific effects of these drugs are still unknown. The objective of this study was to investigate changes of the immediate memory and verbal working memory in patients with chronic schizophrenia after switching to one of four atypical antipsychotic agents and cessation of anticholinergic therapy. The subjects included 77 schizophrenic patients who were treated primarily with typical antipsychotics. Treatment was randomly switched to one of four atypical antipsychotics (olanzapine, perospirone, quetiapine, or risperidone) over a 4-week period, and then the drug was continued for another 4 weeks while the patient was taken off anticholinergics. The immediate memory, verbal working memory, and symptoms were evaluated. Significant improvement of immediate memory was only seen with olanzapine and risperidone. Improvement was also seen after switching to perospirone, but immediate memory worsened after treatment with this anticholinergic drug was discontinued. Deterioration was seen after switching to quetiapine, but immediate memory improved and reached the previous level after treatment with anticholinergic drugs was discontinued. Significant improvement of the verbal working memory was only seen during risperidone administration. The findings suggested that switching chronic schizophrenic patients to atypical antipsychotics can improve both the immediate memory and the verbal working memory when risperidone is used, while improvement of immediate memory can be expected with olanzapine. From the viewpoint of improving the memory, quetiapine should not be administered concomitantly with anticholinergic drugs, and caution should be exercised when discontinuing anticholinergic drugs during treatment with perospirone.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15276691     DOI: 10.1016/j.pnpbp.2004.01.019

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  10 in total

Review 1.  Withdrawal symptoms and rebound syndromes associated with switching and discontinuing atypical antipsychotics: theoretical background and practical recommendations.

Authors:  Anja Cerovecki; Richard Musil; Ansgar Klimke; Florian Seemüller; Ekkehard Haen; Rebecca Schennach; Kai-Uwe Kühn; Hans-Peter Volz; Michael Riedel
Journal:  CNS Drugs       Date:  2013-07       Impact factor: 5.749

2.  The influence of switching from oral risperidone to risperidone long-acting injection on the clinical symptoms and cognitive function in schizophrenia.

Authors:  Hidenobu Suzuki; Keishi Gen
Journal:  Ther Adv Psychopharmacol       Date:  2012-02

Review 3.  Olanzapine versus other atypical antipsychotics for schizophrenia.

Authors:  Katja Komossa; Christine Rummel-Kluge; Heike Hunger; Franziska Schmid; Sandra Schwarz; Lorna Duggan; Werner Kissling; Stefan Leucht
Journal:  Cochrane Database Syst Rev       Date:  2010-03-17

4.  Differential effects of typical and atypical antipsychotics on brain myelination in schizophrenia.

Authors:  George Bartzokis; Po H Lu; Keith H Nuechterlein; Michael Gitlin; Clarissa Doi; Nancy Edwards; Christopher Lieu; Lori L Altshuler; Jim Mintz
Journal:  Schizophr Res       Date:  2007-04-03       Impact factor: 4.939

Review 5.  Risperidone versus other atypical antipsychotics for schizophrenia.

Authors:  Katja Komossa; Christine Rummel-Kluge; Sandra Schwarz; Franziska Schmid; Heike Hunger; Werner Kissling; Stefan Leucht
Journal:  Cochrane Database Syst Rev       Date:  2011-01-19

6.  In vivo evidence of differential impact of typical and atypical antipsychotics on intracortical myelin in adults with schizophrenia.

Authors:  George Bartzokis; Po H Lu; Stephanie B Stewart; Bolanle Oluwadara; Andrew J Lucas; Joanna Pantages; Erika Pratt; Jonathan E Sherin; Lori L Altshuler; Jim Mintz; Michael J Gitlin; Kenneth L Subotnik; Keith H Nuechterlein
Journal:  Schizophr Res       Date:  2009-07-17       Impact factor: 4.939

Review 7.  Quetiapine versus other atypical antipsychotics for schizophrenia.

Authors:  Katja Komossa; Christine Rummel-Kluge; Franziska Schmid; Heike Hunger; Sandra Schwarz; Manit Srisurapanont; Werner Kissling; Stefan Leucht
Journal:  Cochrane Database Syst Rev       Date:  2010-01-20

8.  A computational language approach to modeling prose recall in schizophrenia.

Authors:  Mark Rosenstein; Catherine Diaz-Asper; Peter W Foltz; Brita Elvevåg
Journal:  Cortex       Date:  2014-02-08       Impact factor: 4.027

Review 9.  Pharmacological Interventions for the MATRICS Cognitive Domains in Schizophrenia: What's the Evidence?

Authors:  Wilhelmina A M Vingerhoets; Oswald J N Bloemen; Geor Bakker; Therese A M J van Amelsvoort
Journal:  Front Psychiatry       Date:  2013-12-04       Impact factor: 4.157

10.  Response to: A Commentary on "Antipsychotic-Induced Parkinsonism is Associated with Working Memory Deficits in Schizophrenia-Spectrum Disorders".

Authors:  Stéphane Potvin; Andràs Tikàsz
Journal:  Front Behav Neurosci       Date:  2015-08-12       Impact factor: 3.558

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.